[Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
Radioimmunotherapy in indolent NHL is a new and promising therapy which adds a new therapeutic tool to the treatment palette. Recent advantages in RIT are described and perspectives discussed.
de Nully Brown
Peter
P
H:S Rigshospitalet, Finsencenteret, Haematologisk Afdeling L 4042, og Universitetssjukhuset i Lund, Onkologisk Klinik, Sverige. pbrown@rh.dk
Jurlander
Jesper
J
Lindén
Ola
O
Hansen
Mads
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D016393:Lymphoma, B-Cell / Q000532:radiotherapy; D008224:Lymphoma, Follicular / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan; C119496:tositumomab I-131